HOOPER, LUNDY & BOOKMAN, P.C.
Lobbying for BRAINFUTURES · Nonprofit advocate for therapeutic treatments for mental health and substance use disorder
Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.
Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.
FY2027 budget related to psychedelic therapies for treatment of mental health and substance use disorders.
H.R.2623 - Innovative Therapies Centers of Excellence Act of 2025, S. 4220 - Veterans Health Administration Novel Therapeutics Preparedness Act.